Merck’s Keytruda has hit targets in a Phase III trial investigating its safety and efficacy in patients with previously untreated lung cancer, backing its use in the first-line treatment setting.
News
AZ and MRC Tech form respiratory disease pact
Medical research charity MRC Technology and AstraZeneca are partnering to launch an initiative to find new epigenetic drug targets in respiratory disease.
Marketer of the Year – testing capabilities and stimulating professional growth
PharmaTimes Media invites marketers and teams to enter its prestigious Marketer of the Year competition, designed to benchmark talent within your organisation and across our industry.
BMJ stands with the EU remain campaign
With just days to go until the UK’s landmark vote on whether or not to stay in the European Union, the British Medical Journal has taken the rather unusual step of taking sides in the debate, voicing strong support for the Remain campaign.
NHS diabetes prevention sites ready for referrals
The first sites to take part in the national diabetes prevention programme are gearing up to start taking referrals within a few weeks.
Roche’s Gazyvaro cleared in EU for follicular lymphoma
Roche has won European approval for cancer drug Gazyvaro as a treatment for some patients with previously treated follicular lymphoma, the most common type of indolent non-Hodgkin’s lymphoma.
NICE rejects Roche’s Cotellic for melanoma
The National Institute for Health and Care Excellence is not backing National Health Service use of Roche’s Cotellic/Zelboraf as a treatment for melanoma.
Novo’s Tresiba beats Sanofi’s Lantus on reducing hypoglycaemia
Novo Nordisk has showcased new data from two Phase IIIb trials showing that diabetes patients treated with Tresiba experienced significantly lower rates of several types of hypoglycaemia than those using Sanofi’s Lantus.
Shire buys Pfizer’s investigational IBD biologic
Shire is buying global rights to Pfizer’s investigational biologic PF-00547659 for inflammatory bowel disease.
Late-stage lung cancer diagnosis more likely in younger women
Middle-aged women are more likely to be diagnosed with late-stage lung cancer than older patients, suggest findings of a new analysis by Cancer Research UK.
NHS innovation competition winners unveiled
Health Enterprise East has unveiled the winners of its NHS innovation competition which, for the first time, included a new category that opened the door to industry participants.
Laser surgery for BPH could save NHS £3.2m
NICE is supporting use of Boston Scientific’s laser therapy GreenLight XPS to treat benign prostatic hyperplasia, which could improve outcomes for patients and save the NHS a substantial chunk of cash.
Health and social care leaders call for faster service integration
Experts are warning that the integration of health and social care – which has been a key policy theme for many years – is now at risk because of mounting pressures on services.
Shire picks up two breakthrough badges for rare disease drugs
US regulators have awarded ‘Breakthrough Therapy’ badges to two investigational products being developed by Shire: a novel formulation of budesonide for eosinophilic esophagitis and maralixibat for progressive familial intrahepatic cholestasis type 2.
Teva halts sales of migraine patch on reports of burns, scars
Teva Pharmaceutical Industries has suspended sales of its migraine patch Zecuity following post-marketing reports of burns and scars in patients.
